Andrew V Schally

This inventor holds 38 USPTO granted patents and 13 published patent applications, plus 3 CIPO patents and 6 EPO patents, primarily in Growth Hormone Research. Top assignees: The Administrators of the Tulane Educational Fund, The United States Government as Represented by the Department of Veterans Affairs, University of Miami. Active years: 1977-2025.

USPTO Granted Patents = 38 (Patent Applications = 13)

% Patents Active = 92.1

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 10)

Average Co-Inventor Count = 2.8

ph-index = 13

Forward Citations = 528(Granted Patents)

Location History:

New Orleans, LA (US) (1989)
Metarie, LA (US) (1989 - 1993)
Metairie, LA (US) (1977 - 2006)
Miami, FL (US) (2008 - 2015)
Miami Beach, FL (US) (2012 - 2024)

Company Filing History:

16 out of 248

The Administrators of the Tulane Educational Fund

patents

12 out of 953

The United States Government as Represented by the Department of Veterans Affairs

Dresden University of Technology

patents

5. 1 out of 72

Augusta University Research Institute, Inc.

7. 8 out of 834,350

Other

patents

where one patent can have more than one assignee

Years Active: 1977-2025

Loading Chart...

Areas of Expertise:

GHRH Agonists

GHRH Antagonists

Ischemic Disorders

Diabetes Treatment

Inflammatory Lung Disease

LHRH Analogues

Cardioprotective Effects

Synthetic GHRH Analogues

Cytotoxic Moieties

Dyslipidemia Treatment

Peptidic Compounds

Somatostatin Analogs

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12377135 - GHRH antagonists for use in a method of treating sarcoidosis (2025-08-05),

2. 11993640 - Treating inflammatory lung disease (2024-05-28),

3. 10555987 - GHRH agonists for the treatment of ischemic disorders (2020-02-11),

4. 10201588 - Materials and methods of treating dyslipidemia (2019-02-12),

5. 9855312 - GHRH agonists for the treatment of ischemic disorders (2018-01-02),

6. 9393271 - GHRH agonists for islet cell transplantation and function and the treatment of diabetes (2016-07-19),

7. 9260504 - N- and C-terminal substituted antagonistic analogs of GH-RH (2016-02-16),

8. 9079974 - GH-RH analogs with potent agonistic effects (2015-07-14),

9. 8980249 - Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets (2015-03-17),

10. 8691942 - N- and C- terminal substituted antagonistic analogs of GH-RH (2014-04-08),

11. 8507433 - Cardioprotective effects of GHRH agonists (2013-08-13),

12. 8227421 - Fluorinated GHRH antagonists (2012-07-24),

13. 8227405 - Fluorinated GHRH antagonists (2012-07-24),

14. 7452865 - Antagonistic analogs of GH RH (2003) (2008-11-18),

15. 7026281 - Antagonistic analogs of GH-RH inhibiting IGF-I and -II (2006-04-11),

Title: The Innovator Andrew V Schally

Introduction: Andrew V Schally, a distinguished inventor hailing from Metairie, LA (US), has made significant contributions to the field of medicine and endocrinology.

Latest Patents: Andrew V Schally holds several patents related to peptide hormone research and cancer treatment, showcasing his innovative approach to healthcare solutions.

Career Highlights: Throughout his illustrious career, Andrew V Schally has been awarded the Nobel Prize in Physiology or Medicine for his groundbreaking research on the brain's production of hormones. His work has revolutionized the understanding and treatment of various endocrine disorders.

Collaborations: Andrew V Schally has collaborated with leading medical institutions and researchers worldwide, further solidifying his reputation as a pioneer in the field of endocrinology.

Conclusion: Andrew V Schally's dedication to advancing medical science through innovative research and patented inventions has left an indelible mark on the healthcare industry, inspiring future generations of inventors and researchers.